'What Is Important to Us' communication program for families of children with severe neurological impairment in the ICU

The "What Is Important to Us" Communication Intervention Pilot Clinical Trial

PHASE2 · Seattle Children's Hospital · NCT06208332

This intervention will try a photo‑narrative communication program with parents of children (6 months–25 years) who have severe neurological impairment in the pediatric ICU and their clinicians to see if it is feasible, acceptable, and helpful.

Quick facts

PhasePHASE2
Study typeInterventional
Enrollment160 (estimated)
Ages6 Months and up
SexAll
SponsorSeattle Children's Hospital (other)
Locations1 site (Seattle, Washington)
Trial IDNCT06208332 on ClinicalTrials.gov

What this trial studies

This is a pilot randomized controlled trial enrolling parents of children with severe neurological impairment and their ICU clinicians at admission. Participants complete baseline surveys before randomization; the intervention arm completes the "What Is Important to Us" photo‑narrative communication intervention while the control arm receives usual care. Post‑intervention surveys are completed within one week of ICU discharge, and semi‑structured interviews are done with intervention‑arm parents and clinicians to guide refinements. The trial measures feasibility, acceptability, and early signals of effect on communication and related outcomes.

Who should consider this trial

Good fit: Ideal candidates are parents/legal guardians and clinicians of children aged 6 months to 25 years who have had severe neurological impairment for more than six months and are admitted to the ICU, with parent caregivers who prefer English or Spanish.

Not a fit: Patients unlikely to benefit include those with expected hospital stays under two days, a life expectancy under four weeks, children who have never previously been home, or families who do not speak English or Spanish or who previously participated in the study.

Why it matters

Potential benefit: If successful, the program could improve clarity between families and clinicians about goals and priorities, reduce decisional stress, and help align care with what matters most to the child and family.

How similar studies have performed: Family‑centered and palliative communication interventions in ICU settings have shown promise for improving communication and satisfaction, but photo‑narrative approaches for children with severe neurological impairment are novel and only minimally tested.

Eligibility criteria

Show full inclusion / exclusion criteria
Children with SNI

Inclusion

* Hospitalized at study sites
* Ages 6 months through 25 years old
* Has had SNI for \>6 months, defined as permanent static or progressive central nervous system injury resulting in motor/cognitive impairment and medical complexity

Exclusion

* Has never previously been home/discharged
* Has an expected hospital length of stay \<2 days
* Has a life expectancy of \<4 weeks
* Previous study participation

Parents

Inclusion

* Parent/legally authorized representative of an eligible child with SNI
* Preferred language of care English and/or Spanish

Clinicians

Inclusion -Licensed physicians, nurses, advanced practice providers, respiratory therapists at study site

Exclusion

-Previous study participation

Where this trial is running

Seattle, Washington

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.

View on ClinicalTrials.gov →

Conditions: Critical Illness, Neurologic Disorder, pediatric palliative care, communication, severe neurological impairment

Last reviewed 2026-05-15 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.